Pergolide
IUPAC: 8β - ( methylthiomethyl )-6- propylergolin
- C19H26N2S ( pergolide )
- C19H26N2S · CH3SO3H ( pergolide mesylate · )
- 66104-22-1 ( pergolide )
- 66104-23-2 ( pergolide mesylate · )
N04BC02
- 314.49 g · mol -1 ( pergolide )
- 410.59 g · mol -1 ( pergolide mesylate · )
- 217.5 ° C ( pergolide )
- 258-260 ° C ( pergolide mesylate · )
Mesylate
Risk
8.4 mg · kg -1 ( LD50, Rat, oral, pergolide )
Template: Infobox chemical / molecular formula search available
Pergolide is a drug that is used for the treatment of Parkinson's disease. Its pharmacological effects mediated this derived from ergot drug via an activation of dopamine receptors (dopamine agonist ).
- 2.1 Mechanism of Action
Clinical information
Application
Pergolide is approved as a single agent and in combination with levodopa and decarboxylase inhibitor a (eg carbidopa ) for the treatment of Parkinson 's disease. In veterinary medicine, pergolide is used as monotherapy for the treatment of Cushing's syndrome in horses.
Interactions
Dopamine antagonists, such as metoclopramide, put down the effectiveness of pergolide. Pergolide potentiates the blood pressure lowering effects of antihypertensive agents.
Side effects
During treatment with pergolide in particular dyskinesia, hallucinations, insomnia, loss of appetite, nausea, hypotension and tachycardia were observed. According to recent studies, pergolide may cause fibrotic valvular damage, which is why it has already been taken in some countries (eg Sweden ) from the market. The side effects of pergolide and other ergoline agents may be motivated partly by the fact that they are dirty drugs, that is, not specifically act on the dopamine receptors, but also to other receptors.
Pharmacological information
Mechanism of Action
Pergolide is an agonist at the dopamine receptors D1 and D2 and their subtypes.
Trade names
Parkotil (D), Permax (A, CH ), numerous generics (D)